Impact of Mutations Conferring Reduced Susceptibility to Lamivudine on the Response to Antiretroviral Therapy

Hertogs K. , Bloor A. , De Vroey V. , van Den Eynde C. , Dehertogh P. , van Cauwenberge A. , Sturmer M. , Alcorn T. , Wegner S. , van Houtte M. , Miller V. , & Larder B.A. A novel human immunodeficiency virus type 1 reverse trascriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184. Antimicrobial Agents & Chemotherapy 2000; 44: 568–573.

Delaugerre C. , Mouroux M. , Yvon-Groussin A. , Agut H. , Katlama C. , & Calvez V. Prevalence and conditions of selection of 44D and/or 118I RT mutations in clinical practice. Antimicrobial Agents & Chemotherapy 2001; 45: 946–948.

Gallego O. , Briones C. , Corrala A. , & Soriano V. Prevalence of novel lamivudine-resistant genotypes (E44D/A, V118I) in naive and pretreated HIV-infected individuals. Journal of Acquired Immune Deficiency Syndrome 2000; 25: 95–96.

d'Arminio Monforte A. , Cozzi Lepri A. , Rezza G. , Pezzotti P. , Antinori A. , Phillips A.N. , Angarano G. , Colangeli V , De Luca A. , Ippolito G. , Caggese L. , Soscia F. , Filice G. , Gritti F. , Narciso P. , Tirelli U. , & Moroni M for the ICONA Study Group. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen and its determinants in a clinical cohort of antiretroviral naïve patients. AIDS 2000; 14: 499–507.

Hirsch M.S. , Brun-Vézinet F. , D'Aquila R.T. , Hammer S.M. , Johnson V.A. , Kuritzkes D.R. , Loveday C. , Mellors J.W. , Clotet B. , Conway B. , Demeter L.M. , Vella S. , Jacobsen D.M. , & Richman D.D. Antiretroviral drug resistance testing in adult HIV-1 infection. Journal of the American Medical Association 2000; 283: 2417–24266.

Schinazi R.F. , Larder B.A. , & Mellors J. Resistance table: mutations in retroviral genes associated with drug-resistance: 1999–2000 update. International Antiviral News 2000; 8: 65–91.